Biodesix Announces Presentations and Events at the CHEST 2025 Annual Meeting

Rhea-AI Summary

Biodesix (Nasdaq: BDSX) announced presentations and events at the CHEST 2025 Annual Meeting, October 19–22 in Chicago. Preliminary CLARIFY study data from the first 1,000 enrolled patients will be presented in a sponsored Learning Theater on October 21 at 2:00 PM CDT by Michael Kammer, PhD.

The CLARIFY study is a real-world retrospective review designed to assess Nodify CDT and Nodify XL2 performance in up to 4,000 patients with ≥1-year follow-up. Multiple independent clinical presentations and a national analysis of pulmonary nodule healthcare resource utilization will also be presented. Biodesix leadership will staff booth #1012.

One year after launch of real-world CLARIFY study, preliminary data from the first 1,000 enrolled patients will be presented

LOUISVILLE, Colo., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, announces educational events, abstracts, and activities at the 2025 CHEST Annual Meeting, October 19-22, in Chicago, Illinois.

Biodesix will be presenting data from an interim analysis of the CLARIFY study in a sponsored Learning Theater presentation.

Title: Driving to a New Standard of Care in Lung Nodule Management: Preliminary Results from the Nodify Lung Real-World CLARIFY Study
Presenter: Michael Kammer, PhD, Head of Radiomics at Biodesix
Location: Learning Theater 4
Date and Time: Biodesix Learning Theatre, October 21 at 2:00 pm CDT
Description: This presentation will review analysis from the first 1,000 patients enrolled in the CLARIFY study. The CLARIFY study began patient enrollment shortly after the 2024 CHEST Annual Meeting and is designed to confirm performance of the Nodify CDT^® and Nodify XL2^® tests in diverse patient subgroups through a retrospective chart review of up to 4,000 patients with at least 1-year follow-up since being tested in a real-world clinical setting. The study’s intent is to expand the extensive evidence characterizing the validation and utility of the Nodify Lung tests.

A national analysis of lung nodules receiving clinical work-up across diverse care settings will also be presented at the meeting, highlighting the need for more structured lung nodule management approaches to optimize efficiency of healthcare resource utilization and improve patient outcomes.

Title: Pulmonary Nodule-related Healthcare Resource Utilization After Diagnosis of Pulmonary Nodule in the United States
Presenting Author: Kimberly Le, PharmD, MS, MBA, Director of Health Economics Outcomes Research at Biodesix
Date and Time: Wednesday, October 22, 10:20 AM

It is important to note that there will be numerous independent presentations by healthcare professionals highlighting the clinical value of the Nodify Lung tests in their own real-world patient populations. Examples are below.

Title: Comparison of the Blood-based Nodify XL2 Test with PET/CT to Evaluate for Malignancy in Indeterminate Pulmonary Nodules in an Endemic Fungal Region
Presenting Author: Michael Torres Lizardi, MD
Date and Time: Sunday, October 19, 11:20 AM CDT

Title: Impact of the Nodify Lung Test Strategy in the Risk Stratification of Lung Nodules in Patients of a Pulmonary Practice in Miami
Presenting Author: Elizabeth Samper Perez
Date and Time: Wednesday, October 22, 10:20 AM CDT

Title: The Association of Lung Cancer Screening (LCS) and Proteomic Lung Nodule Testing in an Unrepresentative Minority Community (UMC) in Brooklyn, NY
Presenting Author: Juan Martinez Zegarra, MD
Date and Time: Wednesday, October 22, 10:20 AM CDT

Title: A Retrospective Analysis of Biodesix Biomarker to Assess Efficacy in Risk Stratification and Reduction of Invasive Surgical Procedures in Detected Solitary Pulmonary Nodules
Presenting Author: Kevin Huynh, DO
Date and Time: Wednesday, October 22, 10:20 AM CDT

In addition, Biodesix executive leaders and medical officers will be present at the Biodesix booth #1012 to discuss the future of biomarkers for lung nodule management and lung health diagnostics.

“It is an exciting time to be part of the lung diagnostics space, with biomarkers poised to transform and improve patient care,” said Scott Hutton, CEO at Biodesix. "With thousands of lung specialists coming together, the CHEST Annual Meeting offers a pivotal moment in lung diagnostics and in the fight against lung cancer. It’s great timing with Lung Cancer Awareness Month starting November 1^st.”

About Biodesix:

Biodesix is a leading diagnostic solutions company, driven to improve clinical care and outcomes for patients. Biodesix Diagnostic Tests, marketed as Nodify Lung^® Nodule Risk Assessment and IQLung^® Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable the world’s leading biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. For more information, visit biodesix.com.

Biodesix Contacts:
Media:
Natalie St. Denis, Director Corporate Communications, Biodesix
natalie.stdenis@biodesix.com
(720) 925-9285

Investors:
Chris Brinzey, Partner, ICR
chris.brinzey@icrhealthcare.com
(339) 970-2843

FAQ

When and where will Biodesix present preliminary CLARIFY study data at CHEST 2025 (BDSX)?

Preliminary CLARIFY data from the first 1,000 patients will be presented on October 21 at 2:00 PM CDT in Learning Theater 4 at CHEST 2025 in Chicago.

What does the CLARIFY study (BDSX) examine and how many patients will it include?

CLARIFY is a real-world retrospective chart review designed to evaluate Nodify CDT and Nodify XL2 in up to 4,000 patients with at least 1-year follow-up.

Who is presenting Biodesix’s Learning Theater on October 21 at CHEST 2025?

Michael Kammer, PhD, Head of Radiomics at Biodesix, is the presenter for the Learning Theater session on October 21.

What other Biodesix sessions about Nodify Lung tests are scheduled at CHEST 2025 (BDSX)?

Multiple independent presentations by clinicians cover comparisons with PET/CT, risk stratification in practice settings, screening associations, and retrospective biomarker analyses across October 19–22.

Will Biodesix executives be available at CHEST 2025 and where can investors find them (BDSX)?

Yes. Biodesix executive leaders and medical officers will be available at booth #1012 to discuss biomarkers for lung nodule management and lung health diagnostics.

What specific healthcare resource analysis will Biodesix present at CHEST 2025 (BDSX)?

A national analysis of pulmonary nodule-related healthcare resource utilization after nodule diagnosis in the U.S. will be presented, highlighting structured management needs.